Table 2.
Variables | β | HR | 95% CI | P-value |
---|---|---|---|---|
Gender (male/female) | −0.279 | 0.757 | 0.440–1.300 | 0.312 |
Age (≤60/>60, years) | 0.101 | 1.107 | 0.716–1.710 | 0.647 |
Cirrhosis (+/−) | −0.360 | 0.698 | 0.324–1.501 | 0.357 |
Tumor size (≤5/5, cm) | 0.495 | 1.641 | 1.089–2.473 | 0.018 |
Tumor number (1/≥2) | 0.800 | 2.225 | 1.549–3.198 | <0.001 |
PVTT | −0.764 | 0.466 | 0.314–0.691 | <0.001 |
Child–Pugh (A/B) | 0.294 | 1.341 | 0.780–2.305 | 0.288 |
BCLC (A/B/C) | 0.391 | 1.478 | 1.211–1.804 | <0.001 |
AFP (≤400/>400, ng/μL) | 0.212 | 1.237 | 0.862–1.775 | 0.249 |
ALT (≤40/>40, U/L) | 0.089 | 1.093 | 0.762–1.569 | 0.628 |
AST (≤40/>40, U/L) | 0.454 | 1.574 | 1.036–2.391 | 0.034 |
ALP (≤150/>150, U/L) | 0.583 | 1.791 | 1.206–2.660 | 0.004 |
GGT (≤50/>50, U/L) | 0.443 | 1.557 | 1.008–2.405 | 0.046 |
PT (<11/11–14.3/>14.3, s) | 0.305 | 1.357 | 0.953–1.933 | 0.091 |
Alb (<34/34–48/>48, g/L) | −0.705 | 0.494 | 0.317–0.771 | 0.002 |
PA (≤200/>200, mg/L) | −0.531 | 0.588 | 0.323–1.071 | 0.083 |
ApoA1 (<1.2/1.2–1.6/>1.6, g/L) | −0.230 | 0.794 | 0.550–1.148 | 0.221 |
HDL-C (≤1.02/>1.02, mmol/L) | −0.157 | 0.855 | 0.589–1.242 | 0.411 |
ApoB (<0.8/0.8–1.05/>1.05, g/L) | 0.295 | 1.343 | 1.060–1.701 | 0.015 |
LDL-C (<2.07/2.07–3.12/>3.12, mmol/L) | 0.180 | 1.198 | 0.922–1.556 | 0.177 |
TBA (≤9.67/>9.67, μmol/L) | −0.072 | 0.930 | 0.637–1.359 | 0.708 |
Abbreviations: AFP, α-fetoprotein; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate transaminase; Alb, albumin; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; BCLC, Barcelona Clinic Liver Cancer; GGT, g-glutamyl transpeptidase; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PA, prealbumin; PT, prothrombin time; PVTT, portal vein tumor thrombus; TBA, total bile acid.